All In Biotech

Drug Trial Radar · NCT06568237

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 349 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

349

Actual

Start

Oct 2, 2024

Primary completion

Sep 15, 2027

Study completion Sep 15, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.

Conditions

  • Multiple System Atrophy

Interventions

  • TEV-56286Drug

    TEV-56286 capsules administered orally

  • PlaceboDrug

    Matching placebo administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For non-EU: Change From Baseline in the Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Score (excluding item 11)Time frame: Baseline to Week 48
  2. For EU: Change From Baseline in the Total UMSARS Score Part I and Part II CombinedTime frame: Baseline to Week 48

Locations

61 sites in 8 countries. Site status is shown where the registry gives one.

  • University of California - San Diego

    La Jolla, California

  • University California Los Angeles Medical Center (Ucla)

    Los Angeles, California

  • MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH)

    Washington D.C., District of Columbia

  • Parkinson's Disease And Movement Disorder Center Of Boca Raton

    Boca Raton, Florida

  • University of South Florida Parkinson's Disease and Movement Disorders Center

    Tampa, Florida

  • Rush University Medical Center-Allergy/ Immunology Center

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Detroit Clinical Research Center, PC

    Farmington Hills, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • NYU Medical Center - Dysautonomia center

    New York, New York

  • Columbia University Medical Center - The Neurological Institute of New York

    New York, New York

  • Duke University School of Medicine - Duke Neurological Disorders Clinic - Morreene Road Location

    Durham, North Carolina

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • University Of Pittsburgh

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center (VUMC)

    Nashville, Tennessee

  • Texas Movement Disorder Specialists

    Georgetown, Texas

  • Integrated Neurology Services

    Alexandria, Virginia

  • Inland Northwest Research

    Spokane, Washington

  • Centre Hospitalier Universitaire (CHU) de Bordeaux

    Bordeaux, France

  • CHU de Caen

    Caen, France

  • CHU - Hospital de la Timone

    Marseille, France

  • Chu De La Pitie-Salpetriere

    Paris, France

  • Centre Hospitalier Universitaire de Toulouse - Hopital Purpan

    Toulouse, France

  • Kliniken Beelitz GmbH - Neurologisches Fachkrankenhaus fuer Bewegungsstoerungen / Parkinson

    Beelitz, Germany

  • Universitatsklinikum Carl Gustav Carus an der Technischen Universitat Dresden

    Dresden, Germany

  • University Hospital Duesseldorf

    Düsseldorf, Germany

  • Paracelsus-Elena-Klinik

    Kassel, Germany

  • Universitaetsklinikum Leipzig

    Leipzig, Germany

  • Universitatsklinikum Giessen und Marburg GmbH

    Marburg, Germany

  • LMU - Klinikum der Universitaet Muenchen - Campus Grosshadern

    München, Germany

  • Universitaetsklinikum Muenster

    Münster, Germany

  • University Of Ulm

    Ulm, Germany

  • Rambam Health Care Campus (RHCC)

    Haifa, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • The Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • IRCCS Institute of Neurological Sciences of Bologna- Universita di Bologna

    Bologna, Italy

  • Clinica Neurologica-Aou Policlinico-Vittorio Emanuele-Po G. Rodolico

    Catania, Italy

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario Sa

    Milan, Italy

  • Azienda Ospedale Universita Padova

    Padova, Italy

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.